Skip to content
  • Events
  • Testimonials
  • InstaVisit 360° Virtual Tour
  • Contact Us
  • Events
  • Testimonials
  • InstaVisit 360° Virtual Tour
  • Contact Us
  • About Us
    • Leadership
    • Awards and Recognitions​
    • Certifications
    • Quality Management
    • Environmental, Social and Governance
    • Environment, Health, Safety & Sustainability
    • Corporate Social Responsibility
    • SBTi commitment
    • Suppliers’ Corner
  • Solutions
    • Small Molecules
    • Discovery
    • Chemistry
    • Biology
    • Safety Assessment
    • Computational & Data Sciences
    • Translational And Clinical Research
    • Development
    • Chemical Development
    • Formulation Development
    • Analytical Development
    • Manufacturing
    • Commercial Manufacturing
    • Sterile Fill-Finish
    • Biologics
    • Discovery
    • Molecular Biology
    • Protein Sciences
    • Cell Line Development & Analysis
    • Antibody Generation
    • Bioanalytical Laboratory Services
    • Development & Manufacturing
    • Biologics CDMO Services
    • Analytical Characterization & Quality Control
    • Viral Testing and Clearance
    • Mammalian Gene to GMP timeline tool
    • Early Phase Innovator
    • Synvent Integrated Drug Discovery
    • Other Drug Modalities
    • Peptides
    • Oligonucleotides
    • Antibody Drug Conjugates
    • PROTACs
    • Rare and Orphan Diseases
    • CAR-T
    • pDNA & mRNA
    • Central Compound Management Facility
  • Industries
  • Emerging Biopharma
  • Dedicated Centers
  • Center For Advanced Protein Studies (CAPS)
  • Investors
    • Overview
    • Investor Fact Sheet
    • Financial Information
    • Corporate Governance
      • Governance Structure
      • Board of Directors
      • Committees to the Board
      • Our Leadership
      • Corporate Structure
      • Governance Reports & Policies
    • Share holder services
    • Stock Exchange Disclosures
    • Analyst Coverage
    • Investor Contact
    • Annual Reports
    • ESG Reports
    • Disclosures under Regulation 46 of the LODR
  • Careers
  • Newsroom
    • Press Releases
    • Media Articles
    • Press Kit
    • Syngene Logos
    • Photo Gallery
    • FAQs
  • Insights & Resources
    • Blogs
    • Brochures
    • Viewpoints
    • Scientific Posters
    • Publications
    • Webinars
    • Case Studies
    • White Papers
    • Videos
    • Life at Syngene
    • Newsletters
  • Group Companies
    • Biocon
    • Biocon Biologics
    • Biocon Academy
  • Events
  • Testimonials
  • InstaVisit 360° Virtual Tour
  • Contact Us
  • About Us
    • Leadership
    • Awards and Recognitions​
    • Certifications
    • Quality Management
    • Environmental, Social and Governance
    • Environment, Health, Safety & Sustainability
    • Corporate Social Responsibility
    • SBTi commitment
    • Suppliers’ Corner
  • Solutions
    • Small Molecules
    • Discovery
    • Chemistry
    • Biology
    • Safety Assessment
    • Computational & Data Sciences
    • Translational And Clinical Research
    • Development
    • Chemical Development
    • Formulation Development
    • Analytical Development
    • Manufacturing
    • Commercial Manufacturing
    • Sterile Fill-Finish
    • Biologics
    • Discovery
    • Molecular Biology
    • Protein Sciences
    • Cell Line Development & Analysis
    • Antibody Generation
    • Bioanalytical Laboratory Services
    • Development & Manufacturing
    • Biologics CDMO Services
    • Analytical Characterization & Quality Control
    • Viral Testing and Clearance
    • Mammalian Gene to GMP timeline tool
    • Early Phase Innovator
    • Synvent Integrated Drug Discovery
    • Other Drug Modalities
    • Peptides
    • Oligonucleotides
    • Antibody Drug Conjugates
    • PROTACs
    • Rare and Orphan Diseases
    • CAR-T
    • pDNA & mRNA
    • Central Compound Management Facility
  • Industries
  • Emerging Biopharma
  • Dedicated Centers
  • Center For Advanced Protein Studies (CAPS)
  • Investors
    • Overview
    • Investor Fact Sheet
    • Financial Information
    • Corporate Governance
      • Governance Structure
      • Board of Directors
      • Committees to the Board
      • Our Leadership
      • Corporate Structure
      • Governance Reports & Policies
    • Share holder services
    • Stock Exchange Disclosures
    • Analyst Coverage
    • Investor Contact
    • Annual Reports
    • ESG Reports
    • Disclosures under Regulation 46 of the LODR
  • Careers
  • Newsroom
    • Press Releases
    • Media Articles
    • Press Kit
    • Syngene Logos
    • Photo Gallery
    • FAQs
  • Insights & Resources
    • Blogs
    • Brochures
    • Viewpoints
    • Scientific Posters
    • Publications
    • Webinars
    • Case Studies
    • White Papers
    • Videos
    • Life at Syngene
    • Newsletters
  • Group Companies
    • Biocon
    • Biocon Biologics
    • Biocon Academy
  • Events
  • Testimonials
  • InstaVisit 360° Virtual Tour
  • Contact Us
  • Events
  • Testimonials
  • InstaVisit 360° Virtual Tour
  • Contact Us
  • Events
  • Testimonials
  • InstaVisit 360° Virtual Tour
  • Contact Us
  • About Us
    • Leadership
    • Awards and Recognitions​
    • Certifications
    • Quality Management
    • Environmental, Social and Governance
    • Environment, Health, Safety & Sustainability
    • Corporate Social Responsibility
    • SBTi commitment
    • Suppliers’ Corner
  • Solutions
    • Small Molecules
      • Discovery
        • Chemistry
        • Biology
        • Safety Assessment
        • Computational & Data Sciences
        • Translational and Clinical Research
        Development
        • Chemical Development
        • Formulation Development
        • Analytical Development
        Manufacturing
        • Commercial Manufacturing
        • Sterile Fill-Finish
    • Biologics
      • Discovery
        • molecular biology
        • protein sciences
        • Cell line development & analysis
        • antibody generation
        • Bioanalytical Laboratory Services
        Development & Manufacturing
        • Development and Manufacturing Services
        • Analytical Characterization & Quality Control
        • Viral Testing & Clearance
        • Mammalian Gene to GMP timeline tool
        • mAb Accelerator Program
    • Other Drug Modalities
        • Peptides
        • Oligonucleotides
        • Antibody Drug Conjugates
        • PROTACs
        • CAR-T
        • pDNA & mRNA
        • Rare and Orphan Diseases
        • Central Compound Management Facility
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
        • Animal Health
        • Pharmaceutical & Biotech
        • Agrochemical
        • Nutrition
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
  • Investors
    • Investors
      • Overview
      • Investor Fact Sheet
      • Financial Information
      • Annual Reports
      • ESG Reports
      • Disclosures under Regulation 46 of the LODR
      Corporate Governance
      • Governance Structure
      • Board of Directors
      • Committees to the Board
      • Our Leadership
      • Corporate Structure
      • Governance Reports & Policies
      • Share Holder Services
      • Stock Exchange Disclosures
      • Analyst Coverage
      • Investor Contact
  • Careers
  • Newsroom
    • Press Releases
    • Media Articles
    • Press Kit
    • Syngene Logos
    • Photo Gallery
    • FAQs
  • Insights & Resources
    • Blogs
    • Brochures
    • Viewpoints
    • Scientific Posters
    • Publications
    • Webinars
    • Case Studies
    • White Papers
    • Videos
    • Life at Syngene
    • Newsletters
  • Group Companies
    • Biocon
    • Biocon Biologics
    • Biocon Academy

Archives

Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer

How Syngene is supporting clients in treating cancer using targeted protein degradation, protein stabilization approaches, and precision medicine therapies.

Viral clearance from conventional to unconventional process steps in Biologics

Learn how viral clearance from unconventional steps can add value to the total viral clearance independently or along with conventional process steps.

How Syngene supported a clinical-stage oncology company in manufacturing the RSM for treating a rare tumour

Learn how Syngene reduced the number of steps required to synthesize an RSM for two API candidates by 50% and successfully manufactured and supplied the GMP product to the client.

Detection and quantitation of process-related impurities in biopharma manufacturing

Learn the challenges in the detection and quantitation of process-related impurities, including nitrosamine and azido impurities, and Syngene’s capabilities and solutions to resolve them.

Holistic, mechanism-driven approach to toxicity assessment using Computational and Data Sciences

Learn how Syngene provides in silico and in vitro support for holistic toxicity assessment using Computational & Data Sciences.

Small Molecule Development and Manufacturing

Syngene’s offers an end-to-end platform to deliver integrated and standalone services for small molecules across the Development continuum.

Characterization of acquired resistance mutations to menin inhibitors

Publication: American Association for Cancer Research

LP-07 In silico analysis using Derek and Sarah along with ICH M7 expert review accurately predicts Mutagenicity and Carcinogenicity of Nitrosamines

Publication: Toxicology Letters

Challenges in setting permitted daily exposure limits for pharmaceuticals: A review

Publication: National Library of Medicine; International Journal of Risk & Safety in Medicine

Approaches for setting occupational exposure limits in the pharmaceutical industry

Publication: Journal of Applied Toxicology Wiley

← Previous
Next →

Explore more

Blog

Read our blogs for industry insights and best practices…

More
More

Instavisit

Visit Syngene virtually via our 360 degree lab tours…

More
More

Webinar

View our webinars on cutting edge science topics and insights…

More
More

Viewpoint

Read our latest Viewpoints and White papers….

More
More

Get in touch

Sign-up for our newsletter

© 2026. Syngene International Limited

Linkedin-in Youtube Facebook-f

Quick links

  • About Us
  • Investors
  • Careers
  • News & Events
  • Insights & Resources
  • InstaVisit 360° Virtual Tour
  • Sitemap
  • About Us
  • Investors
  • Careers
  • News & Events
  • Insights & Resources
  • InstaVisit 360° Virtual Tour
  • Sitemap

Business

  • Discovery
  • Development
  • Manufacturing
  • SynVent Integrated Drug Discovery
  • Industries
  • Dedicated Centers
  • Center For Advanced Protein Studies (CAPS)

Get in touch

  • Contact Us
  • Investor Contact

Other links

  • Anti-Bribery Anti-Corruption Statement
  • Disclaimer
  • Privacy Policy
  • Cookie Policy
Linkedin-in Youtube Facebook-f

© 2026. Syngene International Limited